The versatile interplay between steatotic liver disease and liver cancer

<p>Nature Reviews Cancer, Published online: 14 April 2026; <a href="https://www.nature.com/articles/s41568-026-00918-y">doi:10.1038/s41568-026-00918-y</a></p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD) are drivers of liver cancer, promoting its development through chronic liver injury and inflammation. In this Review, Rahbari et al. highlight the distinct pathophysiological mechanisms of progression and therapeutic advancements for MASLD and ALD, emphasizing the need for more tailored…